The Current Ratio as of September 2024 (TTM) for Inhibikase Therapeutics, Inc. (IKT) is 2.32

According to Inhibikase Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 2.32. This represents a change of -39.72% compared to the average of 3.85 of the last 4 quarters.

Inhibikase Therapeutics, Inc. (IKT) Historical Current Ratio (quarterly & annually)

How has IKT Current Ratio performed in the past?

The mean historical Current Ratio of Inhibikase Therapeutics, Inc. over the last ten years is 3.11. The current 2.32 Current Ratio has changed 7.37% with respect to the historical average. Over the past ten years (40 quarters), IKT's Current Ratio was at its highest in in the June 2021 quarter at 25.73. The Current Ratio was at its lowest in in the March 2017 quarter at 0.

Inhibikase Therapeutics, Inc. (IKT) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Inhibikase Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Inhibikase Therapeutics, Inc. (IKT) Average Current Ratio

How has IKT Current Ratio performed in the past?

The current Current Ratio of Inhibikase Therapeutics, Inc. (IKT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Inhibikase Therapeutics, Inc. (IKT) Current Ratio vs. Peers

How is IKT’s Current Ratio compared to its peers?

Inhibikase Therapeutics, Inc.’s Current Ratio is less than DiaMedica Therapeutics Inc. (17.82), less than Milestone Pharmaceuticals Inc. (19.13), greater than Seres Therapeutics, Inc. (1.38), less than Oncolytics Biotech Inc. (4.99), less than scPharmaceuticals Inc. (4.84), less than aTyr Pharma, Inc. (6.07), less than Sio Gene Therapies Inc. (0), less than Kaleido Biosciences, Inc. (21.97), greater than Tempest Therapeutics, Inc. (0), greater than AN2 Therapeutics, Inc. (2.17), less than Miromatrix Medical Inc. (10.61), less than PMV Pharmaceuticals, Inc. (3.46), less than Anebulo Pharmaceuticals, Inc. (19.22), less than Nutriband Inc. (5.32), less than Quoin Pharmaceuticals, Ltd. (6.57), less than Longeveron Inc. (3.35), less than RenovoRx, Inc. (4.18), less than Virax Biolabs Group Limited (4.39), less than null (25.94),

Build a custom stock screener for Inhibikase Therapeutics, Inc. (IKT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Inhibikase Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Inhibikase Therapeutics, Inc. (IKT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Inhibikase Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.